» Articles » PMID: 38794310

Ciprofloxacin-Loaded Inhalable Formulations Against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2024 May 25
PMID 38794310
Authors
Affiliations
Soon will be listed here.
Abstract

Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness for LRTI treatment include poor aqueous solubility and therapy resistance. CFX dry powder for inhalation (DPI) formulations were well-tolerated, showing a remarkable decline in overall bacterial burden compared to a placebo in bronchiectasis patients. Recent research using an inhalable powder combining phage PEV20 with CFX exhibited a substantial reduction in bacterial density in mouse lungs infected with clinical strains and reduced inflammation. Currently, studies suggest that elevated biosynthesis of fatty acids could serve as a potential biomarker for detecting CFX resistance in LRTIs. Furthermore, inhaled CFX has successfully addressed various challenges associated with traditional CFX, including the incapacity to eliminate the pathogen, the recurrence of colonization, and the development of resistance. However, further exploration is needed to address three key unresolved issues: identifying the right patient group, determining the optimal treatment duration, and accurately assessing the risk of antibiotic resistance, with additional multicenter randomized controlled trials suggested to tackle these challenges. Importantly, future investigations will focus on the effectiveness of CFX DPI in bronchiectasis and COPD, aiming to differentiate prognoses between these two conditions. This review underscores the importance of CFX inhalable formulations against LRTIs in preclinical and clinical sectors, their challenges, recent advancements, and future perspectives.

Citing Articles

Murepavadin Enhances the Killing Efficacy of Ciprofloxacin against by Inhibiting Drug Efflux.

Wei X, Zhou D, Xu C, Chen P, Chen S, Cheng Z Antibiotics (Basel). 2024; 13(9).

PMID: 39334985 PMC: 11429200. DOI: 10.3390/antibiotics13090810.


Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives.

Panthi V, Fairfull-Smith K, Islam N Pharmaceutics. 2024; 16(5).

PMID: 38794310 PMC: 11125790. DOI: 10.3390/pharmaceutics16050648.

References
1.
Akkerman-Nijland A, Akkerman O, Grasmeijer F, Hagedoorn P, Frijlink H, Rottier B . The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol. 2020; 17(1):53-68. DOI: 10.1080/17425255.2021.1836157. View

2.
Chono S, Tanino T, Seki T, Morimoto K . Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm. 2008; 34(10):1090-6. DOI: 10.1080/03639040801958421. View

3.
Knudsen K, Northeved H, Kumar P, Permin A, Gjetting T, Andresen T . In vivo toxicity of cationic micelles and liposomes. Nanomedicine. 2014; 11(2):467-77. DOI: 10.1016/j.nano.2014.08.004. View

4.
Wilson R, Welte T, Polverino E, Soyza A, Greville H, ODonnell A . Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2012; 41(5):1107-15. PMC: 3640146. DOI: 10.1183/09031936.00071312. View

5.
Lin Y, Chang R, Britton W, Morales S, Kutter E, Li J . Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections. Eur J Pharm Biopharm. 2019; 142:543-552. PMC: 6750719. DOI: 10.1016/j.ejpb.2019.08.004. View